Back HIV/AIDS

HIV / AIDS

ASM Microbe 2016: HIV Seroconversion Is Rare If PrEP Is Used Consistently

New HIV infections occurred at a low rate of about 1 per 100 person-years among people who took Truvada for pre-exposure prophylaxis (PrEP), with seroconversions mostly seen in those who stopped taking their pills, according to an analysis of more than 30 studies and demonstration projects presented last week at the ASM Microbe 2016 conference in Boston.

alt

ASM Microbe 2016: Atripla 3 Times Weekly Maintains HIV Viral Suppression

People with undetectable viral load who switched from taking the Atripla single-tablet regimen (efavirenz/tenofovir/emtricitabine) every day to just every other weekday were able to maintain viral suppression for 6 months, and longer follow-up is planned, according to research presented last week at the ASM Microbe conference in Boston.

alt

June 27 Is National HIV Testing Day

June 27 is National HIV Testing Day (#NHTD), an opportunity to promote HIV screening and awareness of its importance as a gateway to the continuum of care. According to the Centers for Disease Control and Prevention (CDC), 1 out of 8 of the estimated 1.2 million people living with HIV do not know they are infected, putting their long-term health at risk.

alt

New California Grants Address Disparities in HIV Prevention and Care

An $9 million effort funded by the California HIV/AIDS Research Program (CHRP) will create new interventions tailored to reach heard-to-reach and heavily impacted groups living with or at risk for HIV, including homeless youth, HIV-positive young men of color, young people who use drugs or alcohol, the House Ball community, and women with barriers to care. The new initiative aims to increase HIV testing, treatment initiation, adherence to therapy, and retention in HIV care.

alt

ASM Microbe 2016: PrEP Use Is Rising Fast in U.S., But Large Racial Disparities Remain

More than 49,000 people in the U.S. have filled prescriptions for Truvada for pre-exposure prophylaxis (PrEP) at retail pharmacies, according to the results of a survey by Gilead Sciences presented this week at the ASM Microbe conference in Boston. Among PrEP users with available data, most were white gay men; black people used PrEP much less often, despite having the highest rates of HIV infection.

alt

Less Frequent CD4 and Viral Load Monitoring Safe for People Doing Well on ART

The frequency of routine monitoring for people treated with antiretrovirals who have viral suppression can be safely reduced from every 3 months to every 6 months, investigators from Europe and the U.S. reported in the June 1 edition of the Journal of Acquired Immune Deficiency Syndromes. However, people followed-up every 9 to 12 months were more likely to experience virological failure and also had lower CD4 cell increases compared to people monitored every 3 months.

alt

ASM Microbe 2016: PRO-140 Antibody Injections Maintain Viral Suppression Off ART

Subcutaneous injections of PRO 140, a monoclonal antibody that blocks HIV entry into cells, was well-tolerated and maintained undetectable viral load for more than a year after stopping antiretroviral therapy (ART) in patients with viral suppression, according to a study presented at the ASM Microbe 2016 meeting this week in Boston.

alt